Teva resumes scarce epilepsy drug Finlepsin retard deliveries to Russia

28 February 2025

Israeli drug manufacturer Teva Pharmaceutical Industries (NYSE: TEVA) has resumed the deliveries of the scarce epilepsy drug Finlepsin retard (carbamazepine) to the Russian market, which is aimed to alleviate shortages of the product, reports The Pharma Letter’s local correspondent.

An official spokesman of the company said in an interview with the Russian RBC business paper, in 2025, the company plans to import more than 1 million packages of the drug. Earlier some Russian media reported that parents of disabled children complain about the lack of this drug.

As Teva explained, the suspended deliveries are due to the registered price of the drug, which did not cover production and logistics costs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK